India's Shilpa Medicare up on completing clinical trial of liver disease drug
15/05/2024 06:39
** Shares of Shilpa Medicare SHME.NS rose as much as 3.9%,
last up 1.3% at 513.95 rupees
** Pharma co announced completion of clinical trial of
SML-007 drug for treatment of non-alcoholic fatty liver disease
** Nifty Pharma index .NIPHARM , which SHME is not part of,
is up 0.42%
** YTD, stock up 55.8% compared to 12.4% climb in pharma
index
(Reporting by Varun Vyas in Bengaluru)
((varunvyas.hebbalalu@thomsonreuters.com))
Recent news on Shilpa Medicare
See all newsBrief: Shilpa Medicare Q2 Consol Net Profit INR 791.8 Million
Brief: Shilpa Medicare Says USFDA Conducts Surveillance Inspection At Shilpa Medicare Unit
Brief: Shilpa Medicare Receives Final SEC Approval For Oeris Marketing Authorization
India's Shilpa Medicare gains on approval for OERIS
Brief: Shilpa Medicare Initiates Voluntary Recall Of 27,923 Pemetrexed Injection Vials In Us On July 29, 2026